Genemo

Genemo is a United States life-sciences company based in San Diego, California, that positions itself as a service provider for the development of liquid-biopsy diagnostics. Its core commercial offering is SILVER-Seq™ — short for Small Input Liquid Volume Extracellular RNA Sequencing — a sequencing service that profiles extracellular RNAs (exRNAs) from very small volumes of liquid biopsy samples. According to the company's website, the method can sequence both integral and fragmented exRNAs from a droplet of 5–7 microliters of human serum, plasma, saliva, or aqueous humor, making it possible to work with samples as small as a finger prick. Genemo operates as a research-service business rather than a consumer diagnostics brand. Customers order by the number of liquid-biopsy samples they wish to submit; Genemo then provides shipping instructions, receives the samples, performs the SILVER-Seq™ workflow, and returns sequencing data. The company states that it performs 75-cycle single-end sequencing with a minimum of 3 million reads per sample, and delivers FASTQ files, mapping results, and QC reports through its data server. It also provides processed data covering detected exRNAs — including miRNAs, antisense RNAs, and exRNAs derived from lncRNAs and mRNAs — together with expression levels expressed as Tags Per Million (TPM). Sample handling is a central part of the service. Genemo accepts serum, plasma, saliva, and aqueous humor, requires at least 7 µL per sample (recommending 15 µL or more), and asks that samples be kept in nuclease-free (PCR-clean) tubes and stored at -70 °C to -80 °C. The ordering process begins by email, followed by sample shipment, receipt confirmation, and a pre-analytical quality check. The company presents itself as a partner for researchers and diagnostic developers who need to extract RNA-based signals from limited or precious clinical specimens. Its public materials emphasize publications, experience, and a press release around the SILVER-seq method, indicating a focus on scientific credibility and method validation. Genemo is recorded in Wikidata as a company in San Diego, United States. Beyond its official website and that basic corporate identification, relatively little public information is available about its ownership, funding, founding date, or executive team, so its profile remains that of a specialized, privately held service provider in the extracellular-RNA and liquid-biopsy space.

Genemo is a San Diego, California-based company operating in the life-sciences and molecular-diagnostics services sector. Publicly available information about its corporate history is limited: Wikidata identifies it simply as a company in San Diego, United States, and its official website presents its current service offering rather than a detailed corporate timeline. What can be established from its own materials is that Genemo built its commercial identity around a specific sequencing method, SILVER-seq, which it markets under the trademarked service name SILVER-Seq™. The method's name — Small Input Liquid Volume Extracellular RNA Sequencing — describes its distinguishing feature: the ability to sequence extracellular RNAs from a very small droplet of liquid biopsy. Genemo's website states that SILVER-Seq™ efficiently sequences both integral and fragmented exRNAs from 5–7 microliters of human serum, plasma, saliva, or aqueous humor. This places the company in the broader field of liquid-biopsy research, where the goal is to obtain diagnostic information from body fluids rather than from invasive tissue biopsies. Genemo's service model is built around providing this method as an outsourced workflow. Customers place orders by email based on the number of liquid-biopsy samples they intend to submit. Genemo supplies shipping instructions, receives the samples, performs a pre-analytical quality check, and then carries out the SILVER-Seq™ sequencing. The company reports that it performs 75-cycle single-end sequencing with a minimum of 3 million reads per sample, and returns results including FASTQ files, mapping results, and QC reports via its data server. It also delivers processed data listing detected exRNAs — miRNAs, antisense RNAs, and exRNAs derived from lncRNAs and mRNAs — with expression levels in Tags Per Million (TPM). Sample requirements are specified in detail: serum, plasma, saliva, and aqueous humor are accepted; at least 7 µL is required, with 15 µL or more recommended; samples must be kept in nuclease-free (PCR-clean) tubes and stored at -70 °C to -80 °C. These specifications indicate that Genemo targets research laboratories and diagnostic developers that work with limited or difficult-to-obtain clinical specimens. The company's website also references publications, experience, and a press release related to SILVER-seq, suggesting an emphasis on scientific validation and method development. However, details such as the founding date, founders, funding history, ownership structure, and executive leadership are not provided in the available evidence. As a result, Genemo's history is best understood as the development and commercialization of a specialized extracellular-RNA sequencing service rather than a long, publicly documented corporate narrative.

A specialized research-service provider helping customers develop liquid-biopsy diagnostics based on extracellular RNA from very small sample volumes.

• SILVER-Seq™

  Small Input Liquid Volume Extracellular RNA Sequencing service that sequences integral and fragmented extracellular RNAs from 5–7 µL of serum, plasma, saliva, or aqueous humor, delivering FASTQ files, mapping results, QC reports, and processed expression data in TPM.

1. 1Genemo — Help you need for developing liquid biopsy diagnosticsrnadiagnosis.com
2. 2Genemo (United States) — Wikidatawikidata.org